Vericel Corporation

    Jurisdiction
    United States
    LEI
    54930076YM3PLTDR4B91
    ISIN
    US92346J1088 (VCEL)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    53 / 100
    Better than peer group:
    48 / 100
    Fair value (Benjamin Graham formula)
    €19.18 46.0% overvalued
    Financial strength (Piotroski F-Value)
    8 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. Read full profile

    Fundamentals

    Net revenue
    €212.49M
    Gross margin
    73.5%
    EBIT
    €1.02M
    EBIT margin
    0.5%
    Net income
    €6.06M
    Net margin
    2.9%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €287.01M +35.1% €26.60M +338.7%
    €351.33M +22.4% €47.88M +80.1%
    €448.04M +27.5% €81.34M +69.9%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Hopper Jonathan Mark Chief Medical Officer -10K $35.77 -$357.70K
    MCLAUGHLIN KEVIN F N/A -7K $35.92 -$251.44K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 48K $2.12M -42K Sell

    Earnings Calls

    Latest earnings call: July 31, 2025 (Q2 2025)

    Add to watchlist

    Notifications